TOKYO -- A Japanese government expert panel gave the green light to Merck's antiviral pill molnupiravir on Friday, making it the country's first oral treatment against COVID.
Coronavirus
Japan OKs Merck's oral COVID pill molnupiravir
Treatment drug already approved in nations including U.S., U.K. and Philippines
Merck's molnupiravir prevents RNA viruses from replicating within the body. It reduces the risk of hospitalization and death among high-risk COVID patients by 30%. © Reuters
Read Next
Latest on Coronavirus
